What analysts say:
- Buy, sell, or hold?: Analysts are bullish on Haemonetics as four analysts rate it as a buy and only one analyst rates it as a sell. Analysts like Haemonetics better than competitor C.R. Bard overall. While analysts still rate the stock a hold, they are a little more optimistic about it compared to three months ago.
- Revenue Forecasts: On average, analysts predict $173.6 million in revenue this quarter. That would represent a rise of 4% from the year-ago quarter.
- Wall Street Earnings Expectations: The average analyst estimate is earnings of $0.77 per share. Estimates range from $0.73 to $0.85.
What our community says:
CAPS All-Stars are solidly behind the stock with 100% awarding it an "outperform" rating. The community at large agrees with the All-Stars with 97.6% granting it a rating of "outperform." Fools are bullish on Haemonetics, though the message boards have been quiet lately with only 45 posts in the past 30 days. Haemonetics has a bullish CAPS rating of five out of five stars that is about on par with the Fool community assessment.
Haemonetics' profit has risen year over year by an average of more than twofold over the past five quarters. Revenue has now gone up for three straight quarters.
Now let's look at how efficient management is at running the business. Traditionally, margins represent the efficiency with which companies capture portions of sales dollars. The following table shows gross, operating, and net margins over the past four quarters.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.